150.16MMarket Cap-1.99P/E (TTM)
23.8000High21.5082Low101.04KVolume23.8000Open23.8500Pre Close2.29MTurnover4.35%Turnover RatioLossP/E (Static)6.53MShares92.000052wk High0.85P/B53.51MFloat Cap9.620052wk Low--Dividend TTM2.33MShs Float589.8000Historical High--Div YieldTTM9.61%Amplitude6.0600Historical Low22.6720Avg Price1Lot Size
Instil Bio Stock Forum
loading...
Support and Resistance Levels
There is defined support just below $28, which aligns with recent consolidation days at around 20 days, giving some expectation of long-term support. Resistance can potentially be found at recent highs close to $27.70, which coincides with key psychological barriers and past rapid ...
loading...
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Tuesday, 14th January at 7:00 am
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025
Instil is target...
keep 👀 $Instil Bio (TIL.US)$
Baird's optimism is driven by promising developments in Instil’s PD-L1xVEGF bispecific antibody, especially following positive data from peers like Akeso and Summit. Analysts believe this drug class has strong potentia...
No comment yet